Telehealth CAC Benchmarks: What Top Brands Actually Pay Per Patient in 2026

“Is our CAC good?” is the most common question founders ask on our strategy calls - usually because their agency reports CAC in a vacuum, with no category context. A $250 CAC can be excellent or existential depending on your vertical, AOV, and retention curve.

Across the health and telehealth accounts AdBoost Health manages from Toronto (part of $153M+ in tracked revenue), here’s what acquisition actually costs in 2026, and what separates the brands at the top of the range from the ones at the bottom.

What is a good CAC for a telehealth brand in 2026?

A good blended CAC in 2026 runs roughly $80–$180 for hair loss and dermatology, $120–$280 for mental health, $150–$350 for weight loss and GLP-1, $200–$450 for hormone and longevity, and $40–$110 for subscription supplements. The full ranges, from first ad dollar to converted patient:

Vertical	Typical blended CAC	Strong	Concerning
Weight loss / GLP-1	$150–$350	Under $180	Over $400
Hair loss / dermatology	$80–$180	Under $100	Over $220
Mental health	$120–$280	Under $150	Over $320
Hormone / longevity	$200–$450	Under $250	Over $500
Supplements (subscription)	$40–$110	Under $55	Over $130

Ranges reflect blended CAC across AdBoost Health partner accounts in each vertical over the trailing 12 months, Meta + Google + TikTok combined.

Two caveats that matter more than the table:

1. CAC only means something against LTV. A $350 CAC on a GLP-1 program retaining patients 8+ months at $200/month is a printing press. The same CAC on a 2.5-month retention curve is a slow bankruptcy. (Run your own ratio in the LTV:CAC calculator, or work backwards from margin with the CAC calculator.)
2. Blended vs. paid CAC. Brands with real organic and referral engines report blended CAC 30–50% below their paid CAC. If your agency only reports platform CAC, you’re not seeing the business.

If you’re on the supplements row, the levers behave differently than in prescription telehealth - we broke down how subscription brands hold the bottom of that range in the supplement brand CAC playbook.

Why is telehealth CAC rising - and who is exempt?

CAC is rising because three forces are compounding - auction density, compliance constraints, and privacy-era signal loss - and the only brands exempt are the ones running creative, funnel, and attribution as one system. More GLP-1 entrants keep bidding up the same weight-loss audiences; Meta’s ad standards around health claims, personal attributes, and transformation content shrink the pool of usable creative angles; and signal loss makes platform optimization noisier per dollar. Median CPMs in weight-loss audiences are up again year over year.

But the spread between the best and worst accounts is widening, not narrowing. The brands holding CAC flat while spend scales share three traits:

• Creative velocity. They test 15–25 new variants monthly. Creative is the targeting now; the ad account is just a distribution system. (More on this in our creative system breakdown.)
• Funnel ownership. They treat the lander, intake flow, and checkout as part of the ad. A 20% intake completion lift is a 20% CAC cut with zero media change.
• Clean attribution. Server-side tracking and post-purchase surveys, so budget decisions follow truth instead of last-click fiction.

Which channels deliver the lowest CAC for telehealth?

Google Search delivers the lowest CAC in almost every account, Meta delivers the most volume at an acceptable CAC, and TikTok and YouTube are situational multipliers - not primary engines. What we consistently see by channel:

• Meta is still the volume engine - best cold-traffic CAC at scale for most verticals, if (and only if) the creative engine keeps pace with fatigue. When variant velocity drops below roughly 15 per month, Meta CAC drifts up within two fatigue cycles.
• Google Search delivers the lowest CAC in the account almost everywhere (“semaglutide online consult”-class intent), but it’s demand capture, not creation. It caps out; it doesn’t scale a category. It also comes with a prerequisite: telehealth advertisers need certification under Google’s healthcare and medicines policy before drug-adjacent keywords will serve - in practice, LegitScript certification for anything prescription-adjacent. Brands that skip this step don’t get expensive Search; they get no Search.
• TikTok produces the cheapest top-of-funnel CPMs and the youngest patients, but compliance review is the strictest and volatility is real. It works as a discovery layer feeding retargeting, rarely as the primary engine.
• YouTube is the sleeper for high-consideration verticals (hormones, longevity): expensive per click, strong on qualified consult rates. When the decision cycle is weeks rather than hours, a seven-minute clinician explainer earns a cheaper qualified consult than a Meta ad that wins on CPM.

The pattern: winners run Meta as the engine, Search as the net, and one discovery channel as the multiplier - with budget rebalanced monthly against blended CAC by cohort, not platform-reported ROAS.

How do you actually lower CAC without cutting spend?

Fix intake friction first - it’s the cheapest CAC win in telehealth - then creative mix, then measurement, then scale. Across AdBoost Health partner accounts, this is the order we pull the levers on every new engagement:

1. Kill the intake friction. Health funnels routinely lose 40–60% of motivated clickers in the eligibility/intake flow. Shortening intake and moving qualification later is the cheapest CAC win in telehealth - we regularly see intake completion move 15–25 points just by cutting field count roughly in half and deferring anything the provider can collect at the consult.
2. Rebuild the creative mix around proven angle categories - clinician authority, patient story, mechanism education, price transparency - and let performance reallocate. The goal isn’t one hero ad; it’s a library where winners are indexed and iterated instead of rediscovered.
3. Fix the measurement layer before scaling anything. Scaling on bad attribution just buys the same patients twice. Server-side events plus a post-purchase survey is usually enough to expose where last-click reporting has been lying.
4. Then, and only then, scale spend - into lookalike expansion and new channels, watching marginal (not average) CAC. Average CAC flatters a scaling account; marginal CAC tells you when the next dollar stops working.

Most partners see directional CAC movement within 2 weeks of this sequence; the compounding effect lands around day 31, when the tested creative library, optimized funnel, and clean attribution are working in lockstep. It’s the same sequence our paid media service runs on every new account.

What should you benchmark besides CAC?

Five upstream metrics: CPM by audience, outbound CTR above ~1.2% on cold traffic, lander conversion to intake start above 25%, intake completion above 50%, and 90-day net revenue retention by acquisition cohort. CAC is the scoreboard, not the game - each of these tells you why the scoreboard reads the way it does:

• CPM by audience is your creative health signal. Rising CPM at flat frequency means the platform is losing confidence in your creative before your ROAS shows it.
• Outbound CTR above ~1.2% on cold traffic separates a creative problem from a funnel problem. Below that line, no lander fix will save the CAC.
• Lander-to-intake start above 25% tests the promise match between ad and page. Big gaps here usually mean the ad is selling something the lander doesn’t lead with.
• Intake completion above 50% is where telehealth funnels quietly die. Every abandoned intake is a patient you paid full acquisition cost for and never converted.
• 90-day net revenue retention by cohort is the check on all of the above - cheap patients who churn in month two are the most expensive patients you’ll ever buy.

If any of those are a mystery in your reporting, that’s the audit finding.

Want your numbers benchmarked against accounts in your exact vertical? That’s what the free account audit on our 30-minute strategy call covers - you get a written plan whether we work together or not.